Literature DB >> 11283920

Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.

S R Wallace1, M M Oken, K L Lunetta, A Panoskaltsis-Mortari, A M Masellis.   

Abstract

BACKGROUND: The importance of the bone marrow microenvironment in multiple myeloma is receiving increasing attention. Recent studies have suggested the importance of cytokine production and cell-cell contact by bone marrow stromal cells in the survival of myeloma cells.
METHODS: In the current study, the authors examined bone marrow mesenchymal progenitor cell (MPC) cultures derived from eight multiple myeloma patients (mean age, 58 years) and nine normal donors (mean age, 61 years), with emphasis on cell surface antigens, cytokine, and growth factor expression.
RESULTS: The authors have found, based on analysis of cellular receptors, growth factors, and cytokine expression, that myeloma MPCs are phenotypically and functionally distinguishable from normal donor MPCs. Immunofluorescence analysis of MPC monolayers shows that myeloma MPC cultures expressed reduced cell surface vascular cell adhesion molecule-1 and fibronectin, in contrast with the strong expression found on normal donor MPCs. Furthermore, a subset of myeloma MPCs strongly express intracellular receptor for hyaluronan-mediated motility, whereas normal MPCs do not. Cytokine expression in bone marrow MPC cultures was examined by reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay. Bone marrow MPCs constitutively express interleukin (IL)-1beta, IL-6, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage (GM)-CSF, stem cell factor (SCF), and tumor necrosis factor (TNF)-alpha. In comparison to normal MPCs, multiple myeloma MPCs express increased basal levels of IL-1beta and TNF-alpha. In vitro exposure of MPC cultures to dexamethasone resulted in the down-regulation of IL-6, G-CSF, and GM-CSF in both normal and myeloma MPC cultures. However, dexamethasone treatment significantly increased expression of SCF-1 in myeloma MPCs.
CONCLUSIONS: In myeloma, bone marrow stromal cells provide paracrine factors, through cytokine production and cell-cell contact, which play a role in plasma cell growth and survival. The authors' data indicate differences in bone marrow MPCs, which may be biologically relevant to the growth and survival of myeloma plasma cells. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283920     DOI: 10.1002/1097-0142(20010401)91:7<1219::aid-cncr1122>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

3.  Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.

Authors:  Miki Furukawa; Hiroshi Ohkawara; Kazuei Ogawa; Kazuhiko Ikeda; Koki Ueda; Akiko Shichishima-Nakamura; Emi Ito; Jun-Ichi Imai; Yuka Yanagisawa; Reiko Honma; Shinya Watanabe; Satoshi Waguri; Takayuki Ikezoe; Yasuchika Takeishi
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

4.  Stable changes in mesenchymal stromal cells from multiple myeloma patients revealed through their responses to Toll-like receptor ligands and epidermal growth factor.

Authors:  Meirav Pevsner-Fischer; Sarit Levin; Tal Hammer-Topaz; Yifat Cohen; Felix Mor; Gerard Wagemaker; Arnon Nagler; Irun Robert Cohen; Dov Zipori
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

5.  Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Yuping Wang; Sharmin Khan; Mohammad Heidaran; Ajai Pal; Xiaokui Zhang; Shuyang He; Andy Zeitlin; Stewart Abbot; Herbert Faleck; Robert Hariri; John D Shaughnessy; Frits van Rhee; Bijay Nair; Bart Barlogie; Joshua Epstein; Shmuel Yaccoby
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

Review 6.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

Review 7.  Enhancing the efficacy of mesenchymal stem cell therapy.

Authors:  Michalis Mastri; Huey Lin; Techung Lee
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

9.  Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Gen Suzuki; Techung Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-10-15       Impact factor: 3.575

10.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.